SCHEMBL5651768

SCHEMBL5651768

Nc1ccc(CCN2CCC2)cc1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.64
HRH3 Q9Y5N1 6/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
MBTD1 Q05BQ5 1/20 0.62
L3MBTL3 Q96JM7 1/20 0.62
SLC6A3 Q01959 1/20 0.59
ALDH1A1 P00352 2/20 0.57
TDP1 Q9NUW8 2/20 0.55
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
GFER P55789 1/20 0.52
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49
MAPK1 P28482 1/20 0.49
CYP2C19 P33261 1/20 0.49
THPO P40225 1/20 0.49
MTOR P42345 1/20 0.49
BLM P54132 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1877934 0.96 HRH3 (0.68) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3
SCHEMBL2762024 0.94 HRH3 (0.71) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3
SCHEMBL2761916 0.94 HRH3 (0.71) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3
Hydrochloric Acid SCHEMBL9034274 0.92 HRH3 (0.69) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3
Hydrochloric Acid SCHEMBL916318 0.92 HRH3 (0.69) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3
SCHEMBL11027036 0.84 SIGMAR1 (0.60) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3
SCHEMBL1509554 0.84 LMNA (0.70) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3
SCHEMBL321095 0.82 SIGMAR1 (0.60) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3
Hydrochloric Acid SCHEMBL6965669 0.82 SIGMAR1 (0.68) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3
SCHEMBL2234644 0.82 SIGMAR1 (0.63) SIGMAR1HRH3L3MBTL1MBTD1L3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases CAPRARO HANS-GEORG 2007-09-13 US disclosed
EP-1689747-A1 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
WO-2005054238-A1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases ABL1, PRKCA, PRKCQ SIGMAR1 4023/4885HRH3 1095/4885L3MBTL1 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.